Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.

British journal of haematology - 1 Aug 2022

Volpe Virginia O, Al Ali Najla, Chan Onyee, Padron Eric, Sallman David A, Kuykendall Andrew, Sweet Kendra, Lancet Jeffrey E, Komrokji Rami S

Abstract excerpt

Splicing factor 3B subunit 1 (SF3B1) somatic mutation in the context of therapy-related myelodysplastic syndromes (t-MDS) has not been well defined. In a large cohort of patients with MDS, those with known SF3B1 somatic mutation were compared as de novo MDS (n = 289) and t-MDS with mutant SF3B1 (SF3B1mut ; n = 31). Baseline characteristics, concomitant mutations, and acute myeloid leukaemia (AML) transformation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leukemia, Myeloid, Acute
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myelodysplastic Syndromes

Share to Neoplasms, Second Primary

Share to Phosphoproteins

Share to Prognosis

Share to RNA Splicing Factors

Share to Transcription Factors

Source

Identifiers

PMID: 35751140
DOI: 10.1111/bjh.18319

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.PMID 35751140Read ↗

Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.Semantic proximity Read ↗

SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis.Semantic proximity Read ↗

Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.Semantic proximity Read ↗

SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease processSemantic proximity Read ↗

SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.Semantic proximity Read ↗

Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.Semantic proximity Read ↗

Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.Semantic proximity Read ↗

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.Semantic proximity Read ↗

Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes.Semantic proximity Read ↗

Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes.Semantic proximity Read ↗

Clinical Characteristics and Molecular Profiling of SF3B1-Mutated Myelodysplastic Syndrome (MDS) in a Real-World Practice.Semantic proximity Read ↗

Significance of SF3B1 Mutations in Myeloid Neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.